Evidence for dual mode of action of a thiosemicarbazone, NSC73306: a potent substrate of the multidrug resistance–linked ABCG2 transporter

Chung-Pu Wu, Suneet Shukla, Anna Maria Calcagno, Matthew D. Hall, Michael M. Gottesman, and Suresh V. Ambudkar

Laboratory of Cell Biology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland

Abstract

Multidrug resistance due to reduced drug accumulation is a phenomenon predominantly caused by the overexpression of members of the ATP-binding cassette (ABC) transporters, including ABCB1 (P-glycoprotein), ABCG2, and several ABC family members [multidrug resistance–associated protein (MRP)]. We previously reported that a thiosemicarbazone derivative, NSC73306, is cytotoxic to carcinoma cells that overexpress functional P-glycoprotein, and it resensitizes these cells to chemotherapeutics. In this study, we investigated the effect of NSC73306 on cells overexpressing other ABC drug transporters, including ABCG2, MRP1, MRP4, and MRP5. Our findings showed that NSC73306 is not more toxic to cells that overexpress these transporters compared with their respective parental cells, and these transporters do not confer resistance to NSC73306 either. In spite of this, we observed that NSC73306 is a transport substrate for ABCG2 that can effectively inhibit ABCG2-mediated drug transport and reverse resistance to both mitoxantrone and topotecan in ABCG2-expressing cells. Interactions between NSC73306 and the ABCG2 drug-binding site(s) were confirmed by its stimulatory effect on ATPase activity (140–150 nmol/L concentration required for 50% stimulation) and by inhibition of [125I]iodoarylazidoprazosin photolabeling (50% inhibition at 250–400 nmol/L) of the substrate-binding site(s). Overall, NSC73306 seems to be a potent modulator of ABCG2 that does not interact with MRP1, MRP4, or MRP5. Collectively, these data suggest that NSC73306 can potentially be used, due to its dual mode of action, as an effective agent to overcome drug resistance by eliminating P-glycoprotein–overexpressing cells and by acting as a potent modulator that resensitizes ABCG2-expressing cancer cells to chemotherapeutics.

Introduction

Multidrug resistance (MDR) due to reduced drug accumulation is a phenomenon associated with the overexpression of ATP-binding cassette (ABC) transporters, such as P-glycoprotein (ABCB1), MDR-associated proteins (MRP), and ABCG2 or mitoxantrone resistance-associated protein. These transporters have great clinical significance, given that they can actively efflux a structurally diverse range of chemotherapeutic agents with overlapping specificity (1, 2). ABCG2, also known as the placenta-specific ABC transporter and as the breast cancer resistance protein (3, 4), is a ‘‘half transporter’’ that most likely functions as a homodimer or higher form oligomer (5, 6) and can efflux a variety of anticancer drugs, including mitoxantrone, doxorubicin, topotecan, and SN-38 (7–9). ABCG2 overexpression has been reported in drug-selected carcinoma cell lines (10, 11), and it is also ubiquitously expressed in a variety of stem cells (12, 13). Whereas no clinical trials have yet shown a drug resistance role for ABCG2 in cancer patients (14), inhibitors of ABCG2 have been shown to enhance the efficacy of drugs in mouse preclinical and human clinical trials (15, 16).

Strategies used to circumvent or resolve the reduced drug accumulation conferred by these polyspecific efflux transporters has relied heavily on the development of clinical inhibitors of P-glycoprotein for concurrent administration with chemotherapeutics (17). Although a number of these agents have shown promise in vitro, they have not been successful in clinical trials, probably due to interference with the function of endogenous P-glycoprotein and suboptimal trial design (18). As a result of this, alternative strategies are required to resolve this clinical issue.

Recently, the small molecule thiosemicarbazone NSC73306 was shown to possess a unique property that exploits P-glycoprotein expression and function to induce toxicity (19, 20) while not itself being a substrate for P-glycoprotein (19, 20). As such, NSC73306 represents a novel strategy to combat MDR in cancer therapy by selectively killing P-glycoprotein–expressing drug-resistant carcinoma cells, and it is currently undergoing preclinical evaluation in mouse tumor xenografts alone and in combination with conventional chemotherapeutics, such as doxorubicin.
Due to the fact that the molecular target of NSC73306 is normally associated with drug resistance, it is imperative that its interactions with other drug efflux transporters be explored as part of its preclinical evaluation. Given the overlapping substrate specificity between P-glycoprotein, ABCG2, and to some extent with ABCC1 (16), we have investigated the effect of NSC73306 on transport mediated by a selected group of ABC subfamily members and on ABCG2-mediated transport. Spontaneous mutations in drug-selected cells at amino acid position 482 (from arginine in the wild-type to glycine or threonine in the mutant ABCG2) were shown to have a vital role in both substrate and inhibitor specificity for ABCG2 (21–25). Therefore, both wild-type and mutant ABCG2-overexpressing cells are used to study ABCG2-mediated transport in this study. We observed that NSC73306 does not interact with ABCC1, ABCC4, or ABCC5. However, we show that NSC73306 is transported by ABCG2 in short-term assays, such as [3H]NSC73306 accumulation assays, wherein the level of [3H]NSC73306 inside the cell is significantly reduced by ABCG2 over a period of 30 min. This result is supported by the finding that NSC73306 stimulates ABCG2 ATPase activity in the nanomolar range and by the inhibitory effect of NSC73306 on photolabeling of this transporter with [3H]idoarlyazidoprazosin. Furthermore, NSC73306 and/or modified forms of NSC73306 compete or interfere with ABCG2-mediated transport and sensitize ABCG2-expressing cancer cells to chemotherapeutics. Thus, the dual mode of action of this compound, including its ability to kill P-glycoprotein–expressing cells and potent modulation of ABCG2, may be exploited to increase the efficacy of chemotherapeutics in the clinic.

Materials and Methods

Drugs and Chemicals

NSC73306 and NSC251820 were obtained from Drug Synthesis and Chemistry Branch, Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, NIH. ZD1694 was a generous gift from AstraZeneca Pharmaceuticals. Calcein-AM was purchased from Molecular Probes. Radiolabeled [125I]idoarlyazidoprazosin (2,200 Ci/mmol) was obtained from Perkin-Elmer Life Science. [α-32P]-8-AzidoATP (15–20 Ci/mmol) was obtained from Affinity Labeling Technologies. Radiolabeled [3H]NSC73306 (25 Ci/mmol) was purchased from American Radiolabeled Chemicals, Inc., G418 was procured from RPI Corp., Cell Counting Kit-8 was purchased from Dojindo Molecular Technologies, Inc. The BXP-21 monoclonal antibody was obtained from Kamiya Biomedical Co. Mouse anti–glyceraldehyde-3-phosphate dehydrogenase monoclonal antibody was obtained from Zymed Laboratories (Invitrogen). Mitoxantrone and all other chemicals were purchased from Sigma.

Cell Lines

The human large–cell lung tumor line COR-L23/P and its doxorubicin-selected MRP1-overexpressing variant COR-L23/R were cultured in RPMI 1640 (Life Technologies, Invitrogen), supplemented with 10% FCS and 100 units of penicillin/streptomycin/mL (Invitrogen) at 37°C in 5% CO₂ humidified air. Doxorubicin (0.2 μg/mL) was added to the COR-L23R cell culture medium (26). Parental expressing human embryonic kidney 293 (HEK293) cells, MRP4-expressing HEK293/4.63 cells, and MRP5-expressing HEK293/51 (27, 28) were maintained in DMEM (Life Technologies, Invitrogen), supplemented with 10% FCS and 100 units of penicillin/streptomycin/mL at 37°C in 5% CO₂ humidified air. G418 (80 μg/mL) was added to the MRP1-HEK293 cell culture medium (29). HEK293 cells stably transfected with either empty pcDNA3.1 vector (pcDNA-HEK293) or pcDNA3.1 containing ABCG2 coding arginine 482 (R482-HEK293) were cultured in Eagle’s MEM (Life Technologies, Invitrogen), supplemented with 10% FCS, 100 units of penicillin/streptomycin/mL, and 2 mg/mL G418 at 37°C in 5% CO₂ humidified air (25). MCF-7 cells and sublines were maintained in DMEM supplemented with 10% FCS and penicillin/streptomycin. MCF-7 AdVP3000 (T482-ABCG2) cells were maintained in the presence of 3 μg/mL doxorubicin and 5 μg/mL verapamil, and MCF-7 FLV1000 (R482-ABCG2) cells were cultured in the presence of 1 μg/mL flavopiridol (22, 30). The human colon carcinoma cell line S1 and its drug-resistant subline S1-M1-80 were maintained in RPMI supplemented with 10% FCS and 100 units of penicillin/streptomycin/mL. S1-M1-80 was cultured in 80 μmol/L of mitoxantrone as described previously (8).

Cytotoxicity Assay

Cell Counting Kit-8 assays were used to determine the sensitivities of cells to tested chemicals as described previously (31). Briefly, cells were plated at a density of 2,000 to 3,000 cells per well in 100 μL of culture medium into 96-well plates at 37°C for 24 h before adding drugs to make a final volume of 200 μL. Cells were incubated for an additional 72 h with various concentrations of drugs. Cell Counting Kit-8 reagent was then added into each well and incubated for 2 to 4 h before reading at a wavelength of 450 nm. IC₅₀ values were calculated from fitted dose-response curves obtained from at least three independent experiments.

Fluorescent Drug Accumulation Assay

Efflux assays were carried out using a FACSort flow cytometer equipped with Cell Quest software (Becton Dickinson) as described previously (32, 33). Fluorescent substrates mitoxantrone and calcein were used to study ABCG2-mediated and MRP1-mediated efflux, respectively. Briefly, cells were harvested after trypsinization by centrifugation at 500×g and then resuspended in Iscove’s modified Dulbecco’s medium (Life Technologies, Invitrogen) supplemented with 5% FCS. Mitoxantrone (5 μmol/L) or calcein-AM (0.25 μmol/L) was added to 3×10⁶ cells in 4 mL of Iscove’s modified Dulbecco’s medium in the presence or absence of NSC73306 or fumitremorgin C (FTC), the ABCG2-specific inhibitor, or MK-571, an inhibitor of MRP1. In the MRP1 efflux study, the cells were incubated in a 37°C water bath in the dark for 10 min, whereas for the ABCG2 efflux, cells were preloaded...
FLV1000 cells were incubated with varying concentrations expressing cells by IC\textsubscript{50} values of respective parental cells. 

<table>
<thead>
<tr>
<th>Cell line</th>
<th>Transporter overexpressed</th>
<th>IC\textsubscript{50} (μmol/L)\textsuperscript{a}</th>
<th>RF\textsuperscript{b}</th>
</tr>
</thead>
<tbody>
<tr>
<td>pcDNA3.1-HEK293</td>
<td>—</td>
<td>8.51 ± 1.71</td>
<td>—</td>
</tr>
<tr>
<td>R482-HEK293</td>
<td>ABCG2</td>
<td>8.97 ± 1.60</td>
<td>1.05</td>
</tr>
<tr>
<td>MCF7</td>
<td>—</td>
<td>59.3 ± 12.8</td>
<td>—</td>
</tr>
<tr>
<td>MCF7-ADR</td>
<td>ABCB1 (P-glycoprotein)</td>
<td>9.91 ± 1.30\textsuperscript{c}</td>
<td>0.17</td>
</tr>
<tr>
<td>MCF7-AdVp3000</td>
<td>ABCG2</td>
<td>77.0 ± 13.4</td>
<td>1.30</td>
</tr>
<tr>
<td>MCF7-FLV1000</td>
<td>ABCG2</td>
<td>72.3 ± 13.2</td>
<td>1.22</td>
</tr>
<tr>
<td>S1</td>
<td>—</td>
<td>12.6 ± 3.8</td>
<td>—</td>
</tr>
<tr>
<td>S1-M1-80</td>
<td>ABCG2</td>
<td>12.2 ± 2.8</td>
<td>0.97</td>
</tr>
<tr>
<td>pcDNA-HEK293</td>
<td>—</td>
<td>5.19 ± 1.15</td>
<td>—</td>
</tr>
<tr>
<td>MRP1-HEK293</td>
<td>ABCC1 (MRP1)</td>
<td>4.26 ± 0.85</td>
<td>0.82</td>
</tr>
<tr>
<td>COR-L23/P</td>
<td>—</td>
<td>36.1 ± 3.8</td>
<td>—</td>
</tr>
<tr>
<td>COR-L23/R</td>
<td>ABCC1 (MRP1)</td>
<td>44.9 ± 7.0</td>
<td>1.24</td>
</tr>
<tr>
<td>HEK293</td>
<td>—</td>
<td>7.28 ± 2.00</td>
<td>—</td>
</tr>
<tr>
<td>HEK293/4.63</td>
<td>ABCC4 (MRP4)</td>
<td>9.17 ± 2.79</td>
<td>1.26</td>
</tr>
<tr>
<td>HEK293/5I</td>
<td>ABCC5 (MRP5)</td>
<td>7.38 ± 1.17</td>
<td>1.01</td>
</tr>
</tbody>
</table>

\textsuperscript{a}IC\textsubscript{50} values are mean ± SD calculated from dose-response curves obtained from three duplicate determinations using cytotoxicity assay as described in Materials and Methods.

\textsuperscript{b}RF were calculated by dividing IC\textsubscript{50} values of ABC transporter overexpressing cells by IC\textsubscript{50} values of respective parental cells.

\textsuperscript{c}P < 0.05.

for 5 min and followed by 45-min incubation at 37°C in the dark before being pelleted by centrifugation at 500 x g. The cell pellet was then suspended in 300 μL PBS containing 0.1% FCS and analyzed immediately by flow cytometry.

**[3H]**NSC73306 Accumulation Assays

MCF-7 or MCF-7 FLV1000 cells were grown in monolayers (0.25 × 10\(^6\) per well in 24-well plates) at 37°C. The assay was initiated by incubating cells with 100 μmol/L [\(^3\)H]NSC73306 (25 Ci/mmol). FTC or NSC73306 at 10 μmol/L was added to [\(^{125}\)I]iodoarylazidoprazosin or [\(^3\)H]NSC73306-treated wells and incubated at 32°C for 5 min under subdued light. After incubation, cells were washed with PBS and lysed by 0.3 mL per well trypsin/EDTA at 37°C for 30 min. The cell lysates were transferred to scintillation vials containing 15 mL Bio-Safe II scintillation fluid, and the radioactivity was measured in a scintillation counter. Cells washed with PBS immediately after addition of the assay mix were used as the 0-min time point. The value for accumulated [\(^3\)H]NSC73306 at 0 min was subtracted from a given time point as nonspecific binding of these compounds to the cells. The accumulation of labeled compounds was expressed as picoemperles per 1 million cells. These assays were done at 32°C to slow the rate of efflux from the cells so that the accumulation/efflux could be studied in a time-dependent manner.

**Photoaffinity Labeling of ABCG2 With [\(^{32}\)P]Iodoarylazidoprazosin**

Crude membranes (50 μg/mL) made from the MCF-7 FLV1000 cells were incubated with varying concentrations of NSC73306 for 10 min at room temperature in 50 mmol/L Tris-HCl (pH 7.5), and then 3 to 6 mmol/L [\(^{125}\)I]iodoarylazidoprazosin (2,200 Ci/mmol) was added. The samples were incubated for an additional 5 min under subdued light. The samples were exposed to a UV lamp (365 nm) for 10 min at room temperature. The labeled ABCG2 was immunoprecipitated using the BXP-21 antibody and processed as described previously (34).

**Photoaffinity Labeling of ABCG2 with [\(\alpha-^{32}\)P]8-azidoATP**

Crude membranes from MCF-7 FLV1000 cells were incubated with 25 μmol/L or 50 μmol/L of NSC73306 or 10 mmol/L ATP for 10 min at 4°C in ATPase assay buffer. [\(\alpha-^{32}\)P]8-azidoATP (10 μmol/L, 10 μCi/nmol) was added under subdued light and incubated for an additional 5 min at 4°C. The samples were then illuminated with a UV lamp (365 nm) for 10 min and were separated on a SDS–7% Tris–acetate polyacrylamide gel at constant voltage. The gel was dried under vacuum and was exposed to an X-ray film for 1 to 3 days at −70°C and exposed to Bio-Max MR film at −80°C for 12 to 24 h.

**ATPase Assays**

ATPase activities of ABCG2 in High Five insect cell crude membranes were measured by end-point inorganic phosphate assay as described previously (35, 36). ABCG2-specific ATPase activity was recorded as beryllium fluoride–sensitive ATPase activity. Briefly, the assay measured the amount of inorganic phosphate released over 20 min at 37°C in the ATPase assay buffer [50 mmol/L MES-Tris (pH 6.8), 50 mmol/L KCl, 5 mmol/L Na\(_2\)ATP, 1 mmol/L EGTA, 1 mmol/L ouabain, 2 mmol/L DTT, and 10 mmol/L MgCl\(_2\)] in the absence and presence of 2.5 mmol/L NaF and 0.2 mmol/L beryllium sulfate. The reaction was initiated by the addition of 5 mmol/L ATP and terminated with SDS (final concentration, 2.5%). The amount of inorganic phosphate released was quantified using a colorimetric method (35).

**Western Blot Analysis**

Crude membrane protein was prepared and subjected to electrophoresis on a 7.5% SDS-polyacrylamide gel and transferred onto a nitrocellulose membrane as described previously (30). Each blot was then incubated in blocking buffer (5% (w/v) milk powder in 0.1% TBS-Tween [25 mmol/L Tris-HCl (pH 7.4), 150 mmol/L NaCl, 0.1% Tween 20]) for an hour before the addition of the ABCG2-specific primary antibody (BXP-21, 1: 500 dilution) or anti–glyceraldehyde-3-phosphate dehydrogenase primary antibody (1:2,000 dilution). The secondary antibody used was the horseradish peroxidase–conjugated goat anti-mouse IgG (1:10,000 dilution). Signals were detected using an enhanced chemiluminescence kit (GE Healthcare).

**Statistical Analysis**

Data are mean values ± SD from at least three independent experiments. Differences between any mean values were analyzed by two-sided Student’s t test, and results were considered statistically significant at \(P < 0.05\).
Results

MRP1-Overexpressing, MRP4-Overexpressing, MRP5-Overexpressing, or ABCG2-Overexpressing Cells Are Equally Sensitive to Thiosemicarbazone NSC73306

To investigate whether NSC73306 is specifically toxic to cells that overexpress ABC transporters linked to MDR other than P-glycoprotein, the intrinsic cytotoxicity of NSC73306 in cells overexpressing the ABC transporters, such as P-glycoprotein, MRP1, MRP4, MRP5, and ABCG2, were evaluated (Table 1). To eliminate the possible variability among cell lines, multiple MRP1-overexpressing and ABCG2-overexpressing cell lines were used in this study. ABCG2-expressing HEK (R482-HEK293) cells, human breast carcinoma (MCF7-AdVP3000 and MCF7-FLV1000) cells, and human colon carcinoma (S1-M1-80) cells were used to study ABCG2 function. MRP1-expressing HEK293 cells (MRP1-HEK293) and human large–cell lung tumor (COR-L23/R) cells were used to evaluate MRP1 function. MRP4-expressing and MRP5-expressing HEK293 cells (HEK293/4.63 and HEK293/5I) were used to study MRP4-mediated and MRP5-mediated drug sensitivity, respectively. P-glycoprotein–expressing MCF-7 (MCF7-ADR) cells were used to confirm the effect of NSC73306 on P-glycoprotein–overexpressing cells as described previously (19). The expression levels of each ABC transporter in respective cell lines was confirmed by Western blot analysis (data not shown) as detailed in Materials and Methods.

The resistance factor (RF) was used to compare the relative toxicity of NSC73306 to cells overexpressing

### Table 2. Chemosensitizing effect of NSC73306 on ABC transporter-mediated drug resistance in HEK293 cells

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Concentration (μmol/L)</th>
<th>IC₅₀ (nM) pcDNA-HEK293</th>
<th>IC₅₀ (nM) R482-HEK293</th>
<th>RR¹</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mitoxantrone alone</td>
<td></td>
<td>6.5 ± 0.6</td>
<td>155.6 ± 10.1</td>
<td>24</td>
</tr>
<tr>
<td>+NSC73306</td>
<td>0.5</td>
<td>8.7 ± 1.6</td>
<td>27.7 ± 1.9</td>
<td>4</td>
</tr>
<tr>
<td>+FTC</td>
<td>5</td>
<td>6.9 ± 0.7</td>
<td>10.8 ± 0.6</td>
<td>2</td>
</tr>
<tr>
<td>Topotecan alone</td>
<td></td>
<td>12.5 ± 2.1</td>
<td>174.3 ± 26.3</td>
<td>14</td>
</tr>
<tr>
<td>+NSC73306</td>
<td>0.5</td>
<td>10.2 ± 2.9</td>
<td>46.7 ± 5.1</td>
<td>5</td>
</tr>
<tr>
<td>+FTC</td>
<td>5</td>
<td>10.5 ± 3</td>
<td>8.9 ± 1.8</td>
<td>1</td>
</tr>
</tbody>
</table>

**Relative resistance (RR) values were obtained by dividing IC₅₀ values of ABC transporter–transfected HEK293 cells by IC₅₀ values of the empty vector pcDNA-HEK293–transfected cells.

Abbreviation: RR, relative resistance.

1IC₅₀ values are mean ± SD in the presence and absence of NSC73306 or other tested compounds. The IC₅₀ values were calculated from dose-response curves obtained from at least three independent experiments.

2Relative resistance (RR) values were obtained by dividing IC₅₀ values of ABC transporter–transfected HEK293 cells by IC₅₀ values of the empty vector pcDNA-HEK293–transfected cells.

3P < 0.001.

4P < 0.01.

5P < 0.05.
selected ABC transporters (Table 1). RF indicates the degree of sensitivity due to the expressed ABC transporter and is calculated by dividing IC50 against cells which overexpress the ABC transporter by the IC50 of the respective parental cells. An RF value of >1.0 indicates the ability of the particular ABC transporter to confer resistance to a compound, such as NSC73306, an RF of 1.0 means that NSC73306 is equally toxic to both cell lines, and an RF value of <1.0 indicates that NSC73306 is more toxic to cells which overexpress a particular ABC transporter than to the parental cells. For instance, the RF of MCF7-ADR cells to NSC73306 is calculated as 0.17, which indicates that NSC73306 is more toxic to the P-glycoprotein–overexpressing cells MCF7-overexpressing MCF-7 cells, confirming the results which were previously reported (19). In contrast, NSC73306 was not able to restore drug sensitivity in cells overexpressing MRP1, MRP4, or MRP5 (Table 2). For instance, the presence of NSC73306 was unable to overcome MRP1-mediated etoposide resistance, MRP4-mediated NSC251820 resistance, or MRP5-mediated ZD1694 resistance. Etoposide, NSC251820, and ZD1694 are established substrates of MRP1, MRP4, and MRP5, with relative RFs of 140, 7, and 7, respectively (27, 38, 39). MK-571 (25 μmol/L) and/or quercetin (10 μmol/L) were used as positive controls to reverse drug resistance conferred by MRPs (39).

**Figure 1.** Effect of NSC73306 on mitoxantrone accumulation in wild-type ABCG2-overexpressing R482-HEK293 cells (A) and wild-type MCF-7 FLV1000 and mutant ABCG2-overexpressing MCF-7 Advp3000 cells (B). Cells were resuspended in Iscove’s modified Dulbecco’s medium supplemented with 5% fetal bovine serum. Mitoxantrone (5 μmol/L) was preloaded in the dark at room temperature and then incubated at 37°C for 45 min in the absence (solid line) or presence of 5 μmol/L (A, dotted line), 10 μmol/L NSC73306 (B, dotted line), or 20 μmol/L FTC (gray solid line). The cells were pelleted by centrifugation at 500 x g and resuspended in 300 μL of PBS containing 0.1% bovine serum albumin. Samples were analyzed immediately by using flow cytometry. Representative histograms from three independent experiments. For these experiments, concentrations ranging from 1 to 50 μmol/L of NSC73306 were used. For clarity, histograms with only indicated concentration of this compound are shown.
NSC73306 Is a Dual Modulator of ABCB1 and ABCG2

Effect of NSC73306 (A) or FTC (B) on photoaffinity labeling of ABCG2 with \( [^{32}P]8\text{-azidoATP} \) or with [\( \alpha^{32}P \)]8-azidoATP (C). Crude membranes (50 μg/mL) from the MCF-7 FLV1000 were incubated with various concentrations of NSC73306 (A) or FTC (B) or 10 mmol/L ATP for 10 min at room temperature, and 3 to 6 mmol/L \([^{125}I]\)iodoarylazidoprazosin or with \([^{32}P]8\text{-azidoATP}\) (10 μCi/nmol; C) were then added. The samples were incubated for an additional 5 min in subdued light. The samples were illuminated with a UV lamp (365 nm) for 10 min at room temperature. The labeled ABCG2 was processed and visualized as described in Materials and Methods. Representative gels from three independent experiments. In all three panels, lane 1 is control without NSC73306 or FTC. In A, lanes 2 to 9 were incubated in the presence of 0.25, 0.5, 1, 2.5, 5, 10, and 20 μmol/L of NSC73306, respectively. In B, lanes 2 to 9 were incubated in the presence of 1, 5, 10, 50, 75, 100, and 200 μmol/L of FTC, respectively. In C, lanes 2, 3, and 4 were incubated with 25 μmol/L NSC73306, 50 μmol/L of NSC73306, and 10 mmol/L ATP, respectively.

![Figure 2](image-url)

**Figure 2.** Effect of NSC73306 (A) or FTC (B) on photoaffinity labeling of ABCG2 with \( [^{32}P]8\text{-azidoATP} \) or with \([^{32}P]8\text{-azidoATP}\) (C). Crude membranes (50 μg/mL) from the MCF-7 FLV1000 were incubated with various concentrations of NSC73306 (A) or FTC (B) or 10 mmol/L ATP for 10 min at room temperature, and 3 to 6 mmol/L \([^{125}I]\)iodoarylazidoprazosin or with \([^{32}P]8\text{-azidoATP}\) (10 μCi/nmol; C) were then added. The samples were incubated for an additional 5 min in subdued light. The samples were illuminated with a UV lamp (365 nm) for 10 min at room temperature. The labeled ABCG2 was processed and visualized as described in Materials and Methods. Representative gels from three independent experiments. In all three panels, lane 1 is control without NSC73306 or FTC. In A, lanes 2 to 9 were incubated in the presence of 0.25, 0.5, 1, 2.5, 5, 10, and 20 μmol/L of NSC73306, respectively. In B, lanes 2 to 9 were incubated in the presence of 1, 5, 10, 50, 75, 100, and 200 μmol/L of FTC, respectively. In C, lanes 2, 3, and 4 were incubated with 25 μmol/L NSC73306, 50 μmol/L of NSC73306, and 10 mmol/L ATP, respectively.

Because NSC73306 binds specifically to the substrate-binding site(s) of ABCG2, a \([^{3}H]\)NSC73306 accumulation assay was done to determine whether NSC73306 is a transport substrate of ABCG2. The initial linear rate (0–5 min) of 25 mmol/L \([^{3}H]\)NSC73306 accumulation in the parental MCF-7 cells (Fig. 3, open squares) was significantly higher (~4-fold higher) than in the ABCG2-overexpressing
MCF-7 FLV1000 cells (open circles), whereas the level of accumulation remained constant after ~5 min. Moreover, the rate and the total accumulation of [3H]NSC73306 in MCF-7 and MCF-7 FLV1000 cells are identical in the presence of the known ABCG2 inhibitor FTC, 10 µmol/L (filled symbols) or if the assays were carried out at 4°C (data not shown).

**NSC73306 Stimulates ABCG2 ATPase Activity**

The effect of NSC73306 on ABCG2-mediated ATP hydrolysis was examined using High Five insect cells overexpressing ABCG2. NSC73306 stimulates beryllium fluoride–sensitive basal ABCG2 ATPase activity in a concentration-dependent manner with maximum stimulation of 3-fold with the concentration required for 50% stimulation in the range of 140 to 150 nmol/L (n = 3; Fig. 4A), which is significantly lower than FTC, with the apparent Kᵢ of ~1.0 µmol/L (40). In comparison, the ABCG2 substrate mitoxantrone also stimulated ABCG2 ATPase activity in a concentration-dependent manner but only to ~2-fold of the basal level with the concentration required for 50% stimulation at 12.3 µmol/L (Fig. 4B). Moreover, increasing concentrations of mitoxantrone (up to 20 µmol/L) had no significant effect on NSC73306 (0.2 µmol/L)–stimulated ABCG2 ATPase activity (Fig. 4B). In contrast to mitoxantrone, the presence of another known ABCG2 substrate phorpeorbide A (up to 20 µmol/L) and ABCG2 inhibitor FTC (up to 5 µmol/L) inhibited NSC73306-stimulated ATP hydrolysis significantly in a concentration-dependent manner, with respective IC₅₀ values of ~1.31 and 0.55 µmol/L (Fig. 4C and D). Phoerpeorbide A itself has a biphasic effect on ABCG2 ATPase activity, stimulating ATP hydrolysis at lower concentrations but inhibiting ATP hydrolysis at higher concentrations (Fig. 4C). The effect of several ABCG2 modulators and substrates, such as curcumin I, XR9576, GF120918, flavopiridol, and nifedipine, on NSC73306-stimulated ABCG2 ATP hydrolysis was also tested (Fig. 4D). FTC itself inhibits ABCG2 ATP hydrolysis (41), whereas curcumin I (41) and nifedipine (34) stimulate it. XR9576, GF120918, and flavopiridol stimulate ABCG2 ATP hydrolysis with 3-fold, 4-fold, and 2-fold maximum stimulation (data not shown). Despite stimulating ABCG2 ATP hydrolysis, XR9576, GF120918, flavopiridol, and nifedipine failed to have any significant effect on the NSC73306-stimulated ABCG2 ATPase activity. Interestingly, the presence of curcumin I actually further stimulates ABCG2 ATP hydrolysis slightly (Fig. 4D). Moreover, NSC73306 failed to stimulate either beryllium fluoride–sensitive basal MRP1 or MRP4 ATPase activity as expected (Fig. 2; Supplementary data).1

**Discussion**

Thiosemicarbazone-related compounds are well-known to have active antiviral, antibacterial, antimalarial, and anti-hypertensive properties (42), as well as antitumor activity that can overcome resistance to chemotherapeutics (19, 43). Recently, we reported that the small-molecule thiosemcarbazone NSC73306 is significantly more cytotoxic to cells that overexpress P-glycoprotein than to cells that do not, and this unique property is directly proportional to functional P-glycoprotein protein expression (19). Therefore, we proposed that NSC73306 could be used to resensitize P-glycoprotein–expressing multidrug resistant carcinoma cells to chemotherapy. However, in addition to P-glycoprotein, the presence of MRPs and ABCG2 is well documented in numerous types of the cancer cells (4) and has been shown to play a major role in the development of MDR in cancer cells (16, 18, 44, 45). For example, ABCG2 and MRP1 are known to transport numerous anticancer chemotherapeutics, whereas MRP4 and MRP5 can transport cyclic nucleotides, as well as prostaglandins, glutathione-conjugated molecules, and various antiviral drugs (16, 21, 44, 46). This prompted us to investigate the potential interactions of NSC73306 with ABCG2, MRP1, MRP4, and MRP5 and the effect of their expression in cell lines on the cytotoxicity of NSC73306.

Although NSC73306 was more cytotoxic to P-glycoprotein–overexpressing cells (RF = 0.17; ref. 19), this selective cytotoxic property of NSC73306 was absent in selected cell lines that overexpress ABCG2, MRP1, MRP4, or MRP5 (Table 1). We did observe that some cell lines are naturally more resistant to NSC73306. It is not unusual for a particular drug to display varying levels of toxicity in cell lines originating from different tissues (41), but in this instance, intrinsic P-glycoprotein levels in the different cell lines may be responsible for differential cytotoxicity. Low levels of MDR1 mRNA are present in HEK293 cells, which are more NSC73306 sensitive (NSC73306 IC₅₀ = 7.29 µmol/L), but MDR1 mRNA is undetectable by reverse transcription–PCR in MCF-7 (NSC73306 IC₅₀ = 59.3 µmol/L) or COR-L23 (NSC73306 IC₅₀ = 36.1 µmol/L) cells (data not shown), consistent with the P-glycoprotein–selective cytotoxicity of
Despite the lack of selective intrinsic cytotoxicity toward ABCG2-expressing cells, NSC73306 is able to resensitize these cells to both mitoxantrone and topotecan (Table 2). This chemosensitizing effect is absent in cells overexpressing MRP1, MRP4, or MRP5. We next showed that NSC73306 not only binds to the substrate-binding site(s) of ABCG2 selectively (Fig. 2), but is also transported by ABCG2 (Fig. 3). ATPase assays showed that NSC73306 elicited a 3-fold stimulation of ABCG2-mediated ATP hydrolysis (Fig. 4), confirming the interaction between NSC73306 and ABCG2; ATP hydrolysis and substrate transport are closely linked events in ABC transporters (47). It is important to note that NSC73306 has much higher affinity for ABCG2 when compared with the known inhibitor FTC (Figs. 2 and 4). In addition, NSC73306 has no effect on the beryllium fluoride-sensitive MRP1 or MRP4 ATPase activity (Fig. 2; Supplementary data),1 confirming the lack of interaction between NSC73306 and the tested MRPs.

Our results suggest that different ABCG2 modulators have different effects on the NSC73306-stimulated ABCG2 ATPase activity (Fig. 4). The ABCG2 substrate mitoxantrone has no effect on NSC73306-stimulated ABCG2 ATPase activity (Fig. 4B). In contrast, NSC73306-stimulated ABCG2 ATPase activity is abolished by increasing concentrations of the ABCG2 substrate pheophorbide A (Fig. 4C) and the ABCG2 inhibitor FTC (Fig. 4D). This suggests that both pheophorbide A and FTC compete with and displace NSC73306 at the ABCG2 substrate-binding site(s), hence eliminating the stimulated ABCG2 ATPase activity. Although mitoxantrone, curcumin I, XR9576, GF120918, flavopiridol, and nifedipine all stimulate ABCG2 ATPase activity by themselves, they have no effect on NSC73306-stimulated ABCG2 ATPase activity (Fig. 4D), either because they bind to an ABCG2 drug-binding site(s) distinct from that of NSC73306 or because they have a lower binding affinity for the same site as NSC73306. Our results are consistent with a recent report by Clark et al. (48) that suggested the presence of at least two drug-binding sites on ABCG2, with possible allosteric communication between them.
The transport data reported here support the notion that reduced accumulation in MCF-7 FLV1000 cells was caused by ABCG2-mediated efflux of [3H]NSC73306 (Fig. 3). A known transport substrate of ABCG2, [125I]idoarlyazidoprazosin (34), was used in our assay to confirm that functional ABCG2 is present in MCF-7 FLV1000 cells. ABCG2-mediated [125I]idoarylazidoprazosin transport was reduced by both FTC and NSC73306, suggesting that [125I]idoarylazidoprazosin, FTC, and NSC73306 all bind in the same substrate-binding pocket of ABCG2 (data not shown). Despite NSC73306 being a transported substrate of ABCG2, this transporter does not confer resistance to it in either HEK293 or MCF-7 cells (Table 1). There are several possible explanations that can produce this result. One possibility is that, in long-term assays, such as the cytotoxicity assay (72 h drug incubation), it may be a metabolite of NSC73306 (including metal complexes, such as iron and copper; ref. 49), which is not an ABCG2 substrate that confers cytotoxicity. Alternatively, NSC73306 insensitivity to lowered cellular accumulation may be due to NSC73306 interacting with an extracellular target. We have shown previously that growing P-glycoprotein expressing KB-V1 cells in the presence of NSC73306 results in the loss of P-glycoprotein expression and consequently the loss of the MDR phenotype (19). In contrast, we found no change in ABCG2 mRNA levels, ABCG2 protein surface expression, or its function after growing ABCG2-overexpressing MCF7-FLV1000 cells in 20 μmol/L NSC73306 for as long as 21 days (data not shown).

In summary, the cytotoxic action of NSC73306 requires the functional expression of P-glycoprotein. Although it is not a substrate or modulator for some of the ABC transporter (ABCC1, ABCC4, and ABCC5) transporters implicated in conferring MDR, this compound interacts with ABCG2 with high affinity and it is transported by this transporter. It has been shown previously that long-term incubation of NSC73306 with P-glycoprotein–expressing cells results in the reduced expression of P-glycoprotein (19), resensitizing them to conventional chemotherapeutics. Furthermore, NSC73306 can reduce ABCG2-mediated drug efflux of other agents, even at very low concentrations, thus sensitizing ABCG2-expressing cancer cells to chemotherapeutics and also selectively killing P-glycoprotein–expressing multidrug resistant cancer cells. Further work with a mouse model system will provide insight into the suitability of NSC73306 as an agent that can circumvent MDR in cancer cells by inhibiting ABCG2 function and by killing ABCB1-expressing cells.

Acknowledgments

We thank Dr. Susan E. Bates (Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, NIH) for the parental and ABCG2-expressing cell lines, Dr. Piet Borst (The Netherlands Cancer Institute) for the HEK294/4.63 and HEK293/5I cells, Dr. Margery A. Barrand (University of Cambridge) for the human COR-L23/P and its Mrp1-overexpressing variant COR-L23/R cells, Dr. Kapil Mehta (M. D. Anderson) for the MCF-7 and MCF-7/ADR cell lines, Dr. Krishnamachary Nandigama (LCB, National Cancer Institute, NIH) for providing the crude membranes of High Five cells expressing ABCG2, the Developmental Therapeutics Program, Division of Cancer Treatment and Development, National Cancer Institute, for providing NSC251820 and NSC73306, AstraZeneca Pharmaceuticals for providing ZD1694, and George Leiman for editorial assistance.

References

20. Honjo Y, Hrycyna CA, Yan QW, et al. Acquired mutations in the...


33. Sauna ZE, Muller M, Peng XH, Ambudkar SV. Importance of the conserved Walker B glutamate residues, 556 and 1201, for the completion of the catalytic cycle of ATP hydrolysis by human P-glycoprotein (ABCB1). Biochemistry 2002;41:13989–4000.

34. Shukla S, Robey RW, Bates SE, Ambudkar SV. The calcium channel blockers, 1,4-dihydropyridines, are substrates of the multidrug resistance-linked ABC drug transporter, ABCG2. Biochemistry 2006;45:8940–51.


Molecular Cancer Therapeutics

Evidence for dual mode of action of a thiosemicarbazone, NSC73306: a potent substrate of the multidrug resistance-linked ABCG2 transporter

Chung-Pu Wu, Suneet Shukla, Anna Maria Calcagno, et al.


Updated version
Access the most recent version of this article at:
http://mct.aacrjournals.org/content/6/12/3287

Cited articles
This article cites 49 articles, 26 of which you can access for free at:
http://mct.aacrjournals.org/content/6/12/3287.full.html#ref-list-1

Citing articles
This article has been cited by 5 HighWire-hosted articles. Access the articles at:
/content/6/12/3287.full.html#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.